All In Biotech

Drug Trial Radar · NCT07532265

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 512 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

512

Planned (sponsor's estimate)

Start

Jul 16, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Kinaset Therapeutics IncIndustry
Sponsor type
Industry
First posted
Apr 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Conditions

  • Severe Asthma

Interventions

  • FrevecitinibDrug

    Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)

  • PlaceboDrug

    Matching placebo to frevecitinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-BD FEV1Time frame: Week 12

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Research site

    Lancaster, California · Recruiting

  • Research site

    San Jose, California · Recruiting

  • Research site

    Brandon, Florida · Not yet recruiting

  • Research site

    Miami, Florida · Recruiting

  • Research site

    Tampa, Florida · Recruiting

  • Research site

    Chicago, Illinois · Not yet recruiting

  • Research site

    Kansas City, Missouri · Not yet recruiting

  • Research site

    Charlotte, North Carolina · Recruiting

  • Research site

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Research site

    Rock Hill, South Carolina · Recruiting

  • Research site

    Dallas, Texas · Recruiting

  • Research site

    Houston, Texas · Recruiting

  • Research site

    San Antonio, Texas · Recruiting

  • Research site

    Williamsburg, Virginia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.